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adjusting for baseline factors (age, sex, race, region, metropolitan statistical area,
family income, and health insurance coverage) using regression model statistics
(adjusted R2). RESULTS: The overall prevalence of pediatric ADHD was 2.47% (n 
5.82 million). Most of the children were boys (68%), White (84%) and had private
health insurance (62%). Overall mean annual expenditure was $ 4145.87. Adjusted
R2 for the baseline model was 0.1130. When different comorbidity measures were
added to the baseline model the adjusted R2 increased to: 0.1230 (CIS), 0.1566
(D’Hoore version of CCI), 0.1534 (MECI), and 0.1372 (CDS-1). Among different com-
binations, a model consisting of patient baseline characteristics, MECI, and CIS
explained the most variation in healthcare expenditure (adjusted R2  0.1618).
CONCLUSIONS: Models that include comorbidity and functional status measures
performs best in risk adjusting health care expenditure in pediatric ADHD. There is
a greater need to evaluate the use of CIS as a potential risk adjustment tool in
mental and behavioral problems.
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OBJECTIVES: To assess the association of second-generation antipsychotics pre-
scriptions (SGAs) with changes in body mass index (BMI) among adolescents com-
pared to a randomly selected age and gender matched untreated comparison
group. METHODS: A retrospective cohort study was conducted using an ambula-
tory electronic medical record database between January 2004 and July 2009. Anti-
psychotic naïve (no evidence of SGAs during 540 days pre index period) mono-
therapy adolescents 12–19 years with at least one prescription for any SGA during
395 days follow-up period were eligible. The comparison group without antipsy-
chotic prescription was matched (3:1) to the antipsychotic group based on age,
gender, andmonth of SGA. Amaximum follow-up BMI 90 days post index date was
evaluated and percentage change from baseline BMI was calculated. Multivariate
linear regression was conducted to assess the percent change in follow-up BMI
from baseline among antipsychotic users compared to the comparison group con-
trolling for covariates. RESULTS: The mean age (15.35 years, SD 2.27) and gender
(males, 53%) distribution among the antipsychotic group (n793) was similar
(p0.05) to the comparison group (n2,373). The mean percentage increase in
follow-up BMI from baseline for antipsychotic group was significantly higher than
the comparison group (p0.01) except for ziprasidone (p0.05). After adjusting for
covariates, adolescents on olanzapine had the highest percentage increase in fol-
low-up BMI from baseline (5.84%, 95% Confidence Interval [CI], 4.07–7.61) followed
by aripiprazole (4.36%; 95%CI, 3.08–5.64), risperidone (3.65%; 95%CI, 2.61–4.68), and
quetiapine (1.53%; 95% CI, 0.53–2.52) compared to the comparison group. Normal
weight adolescents on antipsychotics had higher percentage increase in follow-up
BMI from baseline compared to overweight or obese. CONCLUSIONS: Treatment
with SGAs is associated with significant increase in BMI among adolescents rela-
tive to amatched comparison group. Interventions to controlweight gain should be
considered in adolescents treated with SGAs.
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OBJECTIVES: To compare, by performing a meta-analysis, the impact of long-acting
injectable antipsychotics (LAIs) versus oral atypical antipsychotics (OAs) on hospital-
izations among schizophrenia patients.METHODS: Using the PubMed database and
major psychiatric conference proceedings, a systematic literature review for January
2000 to June 2011 was performed to identify English-language studies evaluating
schizophrenia patients treated with antipsychotics. Studies reporting hospitalization
rates as a percentage of patients hospitalized or as the number of hospitalizations per
person per year were selected. The primary endpoint for the meta-analysis was per-
centage decrease in hospitalization rates from baseline during treatment. Pooled
treatment-effect estimateswerecalculatedusing random-effectmodels.Meta-regres-
sions adjusted for study-level characteristics to account for the heterogeneity across
studies. A sensitivitymeta-regression analysis estimating the treatment effect on ab-
solute hospitalization rates was also conducted. RESULTS: Fifty-three studies evalu-
ating 81 treatment arms (LAIs  15 arms, 5294 patients; OAs  66 arms, 96,013 pa-
tients) were identified. Reduction in hospitalization rates for LAIswas 24.5 percentage
pointshigher than forOAs (random-effect estimates: LAIs 60.0%vsOAs 35.5%, p
0.018). Based on ameta-regression analysis, controlling for age, sex, refractory schizo-
phrenia, and study characteristics, the adjusted percentage reduction in hospitaliza-
tion rates for LAIs was 36.9 percentage points (adjusted estimates: LAIs  66.4% vs.
OAs 29.5%, p 0.024) higher than forOAs. The sensitivity analysis basedonabsolute
hospitalization rates corroborated these findings (adjustedhospitalization rate during
follow-upwas 12.6% lower for LAIs than for OAs; adjusted estimates: LAIs 13.7% vs.
OAs 26.2%, p 0.033). CONCLUSIONS: Results of this meta-analysis suggest that
LAIs significantly reduce hospitalization rates for schizophrenia patients compared to
OAs.
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OBJECTIVES: To compare the impact of switching to long-acting atypical antipsy-
chotic therapy (LAT) versus continuing with oral antipsychotics (APs) on the recur-
rence of hospitalizations and emergency room (ER) visits among schizophrenia
patients who relapsed.METHODS: Hospital discharge and billing records from the
Premier Perspective™ Comparative Hospital Database (2006Q1-2010Q4) were ana-
lyzed. Adult patients receiving oral APs during a schizophrenia-related hospital-
izationwere identified and further stratified upon their next schizophrenia-related
rehospitalization (ie, relapse) into the following exposure groups: 1) patients
switching to LAT (paliperidone palmitate or risperidone) versus 2) patients con-
tinuing with oral APs. LAT relapse patients were matched 1:3 with oral AP relapse
patients using a propensity score model. The Andersen-Gill extension of the Cox
proportional hazardsmodel was used to assess the impact of LAT versus oral AP on
time to multiple recurrences of hospitalizations and ER visits. RESULTS: A total of
1064 LATpatientswerematchedwith 3015 oral AP patients. LAT and oral AP groups
werewell-balancedwith respect to age (42.5 vs. 42.9 years, p0.2859), gender (43.5%
vs. 45.5% female, p0.2429), race, region, payer, hospital characteristics, admitting
diagnoses, physician specialty, and degree of illness severity (P0.05 for all). Over a
mean 30-month follow-up period, LAT patients were associated with significantly
lower rates of all-cause rehospitalizations (1.27 vs. 1.61, p0.0001) and ER visits
(2.36 vs. 2.68, p0.0195) compared with oral AP patients. Based on Andersen-Gill
models, all-cause rehospitalization rates (hazard ratio [HR]0.82, 95%CI: 0.77-0.87,
p0.0001) and ER visits (HR0.89, 95%CI: 0.87-0.94, p0.0001) were significantly
lower for LAT than for oral AP. Consistently significant results were found when
restricting to mental disorder–related events (rehospitalizations: HR0.86, 95%CI:
0.80-0.92, p0.0001; ER visits: HR0.94, 95%CI: 0.89-0.99, p0.042). CONCLUSIONS:
This hospital database analysis found that in relapsing schizophrenia patients,
LATs were associated with lower rehospitalization and ER-visit rates.
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OBJECTIVES: Internet/computer based Cognitive Behavioral Therapies (iCBT/cCBT)
might serve as a cost-effective alternative to face-to-face psychotherapies. The
purpose of this study was to synthesize the quantitative evidence from random-
ized clinical trials (RCTs) addressing the long term benefits of iCBT/cCBT for pa-
tientswith depression and anxiety.METHODS: Previous studies published through
November 2011 were retrieved from three electronic databases (Scopus, Pubmed,
PsycINFO). The inclusion criteria were English-language RCTs involving partici-
pants with major depressive disorder/depressive symptoms, generalized anxiety
disorder, social phobia, and social anxiety disorder. The iCBT/cCBT interventions
were compared to either some other treatment or to no-treatment control groups
that were followed for1 year. Standardized effect sizes (ES) were calculated from
sample sizes, means and standard deviations for the primary outcome measure
that was most closely related to the principal disorder. A random-effects model
was used to calculate pooled effect sizes ES across the studies. Leave-one-out
sensitivity analysis was also performed. RESULTS: Of the 769 articles identified, 82
were considered for full text retrieval and 10 met all inclusion criteria. The pooled
mean ES from the ten different RCTs from 3 different continents showed no statis-
tically significant difference when i-CBT/c-CBT was compared to active control
[Effect Size (ES), - 0.10 , 95% Confidence Interval (CI), -0.21 to 0.01]. In contrast,
results were significant when compared to placebo control (ES, -0.37, 95% CI: -0.70
to -0.05). No significant benefits for i-CBT/c-CBT in the long-termwere found in the
therapist supported subgroup. Results were robust when sensitivity analysis was
performed. CONCLUSIONS: Evidence regarding the long term benefits of i-CBT/c-
CBT for reducing depression and anxiety in adults are weak. Additional well-de-
signed RCTs involving longer follow-up are needed in order to assess the long-tem
effectiveness of this intervention.
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OBJECTIVES: Schizophrenia is often associated with cognitive deficits (CD). This cov-
ers diverse domains such as learning,memory and language. Cognitive skills arewell-
known predictors of social functioning, and knowledge of outcomes associated to CD
is necessary to develop effective treatment strategies. The purpose of this study is to
describe the schizophrenic population with CD.METHODS:Weworked on data from
the EuroSC cohort (N288 in France, N618 in Germany andN302 in UK). Definition
of CD was based on the cognition subscore of Positive and Negative Syndrome Scale
(PANSS). Patientswith a score lower than themedian of the overall setwere identified
at baseline. As five assessments were performed over 2 years, pathways of patients
with CD were explored. Bivariate analyses were conducted to compare patients with
CD to others in terms of quality of life, functioning, side effects and depression.
RESULTS: On the overall set, mean cognition subscore was 9.67 (SD4.60, Me-
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